[ad_1]
ALAMEDA, California – (BUSINESS WIRE) – Scribe Therapeutics Inc. co-founder Jennifer Doudna, Ph.D., received the 2020 Nobel Prize in Chemistry along with collaborator Emmanuelle Charpentier, Ph.D., for her discovery of CRISPR, the genome editing technology that It has transformed modern science and biomedicine. The two scientists are the first women to jointly win a Nobel Prize.
Doudna published her early work on the CRISPR-Cas9 system and its potential to rewrite the DNA of animals, plants, and microorganisms in 2012. Since then, she has pioneered its application in multiple diagnostic and therapeutic areas, discovering additional CRISPR enzymes that are based on the potential of its original technology and led the global conversation about its risks, opportunities and ethical use.
“Jennifer is an inspiration and mentor to the entire Scribe team. We are delighted to congratulate her on this extraordinary and well-deserved recognition, ”said Benjamin Oakes, CEO and co-founder of Scribe Therapeutics. “The development of CRISPR technology has fundamentally changed the way we can address basic scientific questions and create solutions to some of our greatest challenges. It is thanks to Jennifer’s pioneering work and through her continued guidance that we now have the ability to rewrite DNA and ultimately the history of the disease. ”
Doudna co-founded Scribe to design highly advanced CRISPR-based technologies specifically for therapeutic use and set a new standard of clinical care for millions of people with genetic conditions. Scribe recently revealed the company’s fully integrated platform for gene editing and delivery technologies and announced a research collaboration with Biogen Inc. to design therapies for amyotrophic lateral sclerosis (ALS).
In addition to her position at Scribe, Doudna is Chancellor Li Ka Shing’s Chair in Health and Biomedical Sciences and a Howard Hughes Medical Institute Investigator at the University of California, Berkeley, and chairman and chair of the board of the Institute for Innovative Genomics. . She is also a faculty scientist at Lawrence Berkeley National Laboratory (Berkeley Lab), principal investigator at Gladstone Institutes, and adjunct professor of cellular and molecular pharmacology at the University of California, San Francisco.
The Nobel Prize in Chemistry, awarded annually by the Royal Swedish Academy of Sciences, honors researchers who have made outstanding contributions in this field.
About Scribe Therapeutics
Scribe Therapeutics is a molecular engineering company focused on building best-in-class Live therapies to permanently treat the underlying cause of the disease. Founded by the inventors of CRISPR and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities such as part of an exclusive and permanent platform for CRISPR based genetic medicine. The company is backed by leading individual and institutional investors, including Andreessen Horowitz. For more information on Scribe’s mission to rewrite the history of the disease, visit www.scribetx.com
